NQO1 C609T polymorphism and lung cancer susceptibility: Evidence from a comprehensive meta-analysis
Metrics: PDF 798 views | HTML 1396 views | ?
Jiawen Huang1, Huiran Lin2, Xiaosong Wu1, Weijun Jin1 and Zhidong Zhang1
1Department of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong, China
2Animal Experimental Management Center, Public Technology Service Platform, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China
Zhidong Zhang, email: email@example.com
Keywords: NQO1, C609T, polymorphism, lung cancer, meta-analysis
Received: May 18, 2017 Accepted: August 27, 2017 Published: September 19, 2017
A variety of case-control studies have been performed to assess the correlation between NQO1 C609T polymorphism and the risk of lung cancer, but an explicit consensus has not been reached. We conducted this updated meta-analysis to identify the function of NQO1 C609T polymorphism in lung cancer risk. All relevant literature was retrieved from the PubMed, EMBASE, CNKI, and WanFang databases before April 2017. A total of 37 studies (29 articles) with 8493 cases and 10,999 controls were included. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of relations. We found that the NQO1 C609T polymorphism did not correlate with the risk of lung cancer in the overall analysis. In addition, no statistical significance was observed in the analysis stratified based on ethnicity, control source, quality score, or smoking status. A significant association was found in the subgroup of small cell lung cancer risk. Despite some limitations, this meta-analysis indicates that the NQO1 C609T polymorphism may not be associated with lung cancer risk. However, more epidemiological studies of larger samples and more ethnicities are needed to confirm these results.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.